03.04.2017 Views

DPCA2-2_issue_v3

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Diabetes and bone health<br />

Secondary causes<br />

associated with diabetes<br />

l Coeliac disease<br />

l Graves thyrotoxicosis<br />

l Hypothyroidism<br />

l Hypogonadism<br />

l Vitamin D deficiency<br />

Anti-diabetes medication<br />

l TZDs<br />

l GLP-1 receptor agonists<br />

l DPP-4 inhibitors<br />

l SGLT2 inhibitors<br />

Falls risk<br />

l Diabetic retinopathy<br />

l Diabetic neuropathy<br />

l Obesity<br />

l Hypoglycaemia<br />

Decreased bone<br />

turnover<br />

CKD–MBD secondary to<br />

diabetic nephropathy<br />

Fracture risk<br />

Abnormal bone architecture<br />

Decreased bone mineral density<br />

via collagen cross links<br />

Decreased osteoblast differentiation<br />

Osteoblast dysfunction<br />

Increased osteoclast activity<br />

Increased adipogenesis<br />

Increased AGE<br />

Increased PPAR-gamma<br />

Decreased insulin/<br />

IGF-1 secretion<br />

Oxidative stress<br />

Figure 3. The factors influencing bone health and fracture risk in diabetes. AGE=advanced glycation end-products; CKD–MBD=chronic kidney<br />

disease–mineral and bone disorder; DPP-4=dipeptidyl peptidase-4; GLP-1=glucagon-like peptide-1; IGF-1=insulin-like growth factor-1; PPAR-gamma=<br />

peroxisome proliferator-activated receptor-gamma; SGLT2=sodium–glucose cotransporter 2; TZD=thiazolidinedione.<br />

with type 1 diabetes compared to people<br />

without the condition, the relative risk (RR) for<br />

hip fracture was 3.78 (95% confidence interval<br />

[CI], 2.05–6.98; P

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!